KN21

KN21 is a novel synthetic small molecule, specifically a 4-chloro-benzenesulfonamide derivative, that acts as an AMP-activated protein kinase (AMPK) activator. It is being investigated for its therapeutic potential in treating metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. In preclinical studies, KN21 has demonstrated the ability to reduce hepatic steatosis, lipid accumulation, and liver fibrosis in MASH mouse models. It also attenuates lipid accumulation and the release of reactive oxygen species (ROS) and fibrotic mediators in hepatocyte cells, and inhibits the activation of human hepatic stellate cells, showcasing potent antifibrotic activity.